Crinetics Pharmaceuticals, Inc. 8-K

What Happened
Crinetics Pharmaceuticals, Inc. (CRNX) and Vertex Pharmaceuticals Incorporated entered into a definitive Agreement and Plan of Merger on July 6, 2026 under which Clark Merger Sub, Inc. (a Vertex subsidiary) will merge with and into Crinetics. At closing each outstanding share of Crinetics common stock (subject to limited exceptions) will be converted into the right to receive $85.00 per share in cash. The Crinetics board unanimously approved and recommended the transaction. The parties expect the transaction to close in the third quarter of 2026, subject to stockholder approval and customary closing conditions (including HSR and any required foreign regulatory clearances). Crinetics will file a preliminary proxy (within 10 business days) and convene a stockholder meeting to vote on the merger.

Key Details

• Purchase price: $85.00 per share in cash to holders of outstanding common stock at the Effective Time.
• Equity treatment: Outstanding unvested stock options and RSUs will fully vest pre-close; options with exercise price < $85 will be cashed out for the difference between $85 and the exercise price (less withholding); options with exercise price ≥ $85 will be canceled for no consideration.
• Financing: Vertex has a debt commitment letter for a $4.5 billion unsecured 364-day bridge loan to help fund the transaction; the merger is not conditioned on obtaining that financing.
• Termination fee and timeline: The agreement can be terminated under customary circumstances; a termination fee of $350,474,425 applies in specified situations. The outside date for closing is January 6, 2027 (subject to limited extensions).

Why It Matters
For Crinetics shareholders, the deal would result in a cash payout of $85.00 per share if the merger closes — converting public equity into cash and ending public ownership of Crinetics. The transaction requires shareholder approval and regulatory clearances, so it is not final until those conditions are met. The filing highlights accelerated vesting and cash settlement mechanics for employees and holders of stock-based awards, and discloses Vertex’s financing plan and a significant termination fee, which are important factors that affect deal certainty. Crinetics will file and mail proxy materials with more details; stockholders should read those documents before voting.